Research Article
MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways
Figure 4
Osteoblastic gene expression profiles in osteoblasts after treatment with GDC0623. (a) Osteoblasts were maintained in an osteogenic differentiation medium containing IL-1β or IL-1β plus GDC0623 for 7 days. qPCR analysis of osteogenic gene expression in osteoblasts was performed, relative to internal control GAPDH and normalized to control cells. (b) Immunocytochemical staining of Runx2, OCN, and Col I in osteoblasts after treatment with IL-1β or GDC0623 plus IL-1β for 7 days. Data are expressed as mean ± SD for n = 3. < 0.05 versus the control group, < 0.05 versus the IL-1β groups.
(a) |
(b) |